Evaluating the Effects of a Study Medication on Exercise Function in Type 2 Diabetes

• Status: Active, not recruiting
• Trial end date: 2021-09-01
• Target enrollment: 0
• Participant gender: All

Summary

People who are overweight or who have type 2 diabetes mellitus (T2DM) have higher levels of certain fats in their blood. The blood vessels and heart of most of these individuals do not work normally and people with T2DM also have an impaired ability to perform exercise. The purpose of this study is to use the free fatty acid lowering drug, acipimox, to temporarily decrease the level of fat in the bloodstream of people with T2DM and observe the physiological changes to blood vessel function and exercise capacity and insulin sensitivity. This will help the investigators to understand ways of improving blood vessel function and the ability to exercise effectively in people who are overweight or have T2DM.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Colorado, Denver
• Collaborators: Pfizer; US Department of Veterans Affairs; VA Office of Research and Development
• Treatments: Acipimox; Insulin

Criteria

Inclusion Criteria:

• Sedentary adults not participating in a regular exercise program (≤ one bout of scheduled exercise per week)

• Subjects must have Type 2 Diabetes

• Subjects must be otherwise healthy

• Ages of 30-60 years

• BMI of 25-39 and stable weight for 3 months prior to the start of the study

• Diabetes controlled by diet +/- insulin secretagogues (sulfonylureas or glinides), metformin, or glucose absorption blockers (acarbose).

• Total glycosylated hemoglobin levels (HbA1C) ≤9% (fair control) on current therapy.

Exclusion Criteria:

• Any comorbid condition which could limit exercise performance including Chronic Obstructive Pulmonary Disease (COPD) or asthma

• Concurrent enrollment in an interventional study.

• Any tobacco use either current or within the last year

• Clinically evident distal symmetrical neuropathy, determined by evaluation of symptoms (numbness, paresthesia) and signs (elicited by vibration, pinprick, light touch, ankle jerks), will be excluded.

• Autonomic dysfunction (>20 mm fall in upright BP without a change in heart rate) will be excluded.

• Evidence of ischemic heart disease by history or abnormal resting or exercise electrocardiogram (EKG) (> 1 mm ST segment depression) on screening exercise test.

• Angina or any other cardiovascular, pulmonary or musculoskeletal symptoms

• Presence of systolic blood pressure >190 at rest or >250 with exercise or diastolic pressure >95 at rest or >105 with exercise

• Proteinuria (urine protein >200 mg/dl) or a creatinine > 2 mg/dl, suggestive of severe renal disease

• Proliferative retinopathy

• Insulin, incretin, or glitazone treatment

• Niacin treatment

• History of peptic ulcers

• A history of hereditary angioedema

• C1 esterase deficiency

• Women who are pregnant or breastfeeding

• Use of fibrate drugs